Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New answers, efficacy data in MS
August 2019
SHARING OPTIONS:

OTTAWA, Canada—Preclinical data of Orion Biotechnology Canada Ltd.’s OB-002 (5P12-RANTES) from a murine model of multiple sclerosis (MS) was recently published in Science Translation Medicine. In a new preclinical model of multiple sclerosis that features early-life viral infection in the brain, it was found that sites of cleared virus turn into lesion sites associated with MS-like pathology when autoimmune encephalomyelitis (EAE) is induced. EAE lesions contain inflammatory leukocyte because sites of cleared virus are long-term production sites for CCL5, a ligand of CCR5. Systemic administration of OB-002 was found to fully block the development of the lesions and the associated pathology.
 
“It is very exciting to have identified a possible pathway linking virus infection early in life to MS pathology, and intriguing that it should be dependent on the activation of a single chemokine receptor,” said Prof. Doron Merkler, who led the work.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.